MedTrace Logo

Navigation Brain Stimulation for Evaluation of the Neuroprotective Drug Efficiency in Patients After Ischemic Stroke.

NCT01388738 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2011-12-23

No results posted yet for this study

Summary

Ischemic stroke (IS) causes high mortality and severe disability. To improve outcome it's very important to choose the right way of the management of the patient and an appropriate drugs.

There is a large number of the so-called neuroprotective drugs, which were effective in laboratory, but didn't show positive results in clinical studies with using traditional clinical scales scores as a primary outcome measures.

Specialists suggest, that the investigators could receive better results if the investigators change design of the studies, particularly if the investigators select more precise and sensitive method of assessment.

Aim of this study: to determine the role of navigated brain stimulation (NBS) for evaluation of the changes in the motor centers and motor tracts after administration of different cerebroprotective drugs. (The substances won't be compared to each other).

Conditions

Interventions

DRUG

citicoline

citicoline IV 2000 mg, then citicoline 900 mg/day (300mg\*3 times per day) per os

DRUG

L-Alpha glycerylphosphorylcholine

choline alfoscerate IV 1000mg daily 10 days

DRUG

cerebrolysin

Cerebrolysin IV 10 ml daily 10 days

Sponsors & Collaborators

  • Nycomed

    collaborator INDUSTRY

  • Veropharm

    collaborator INDUSTRY

  • Ever Neuro Pharma GmbH

    collaborator INDUSTRY

  • Clinical Institute of the Brain, Russia

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-10-31
Completion
2011-11-30

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01388738 on ClinicalTrials.gov